Table 1.
Antimicrobial susceptibility profiles of Burkholderia cepacia complex isolates
| Antimicrobial susceptibility | 2018-2019 years |
2020-2022 years |
p | OR |
|---|---|---|---|---|
| n (%) | n (%) | |||
| Meropenem (n=72) | 0.191 | 1.98 | ||
| Susceptible | 19 (67.8) | 23 (52.3) | ||
| Intermediate / Resistant | 9 (32.2) | 21 (47.7) | ||
| TMP-SXT (n=83) | 0.110 | 2.47 | ||
| Susceptible | 28 (84.8) | 35 (70.0) | ||
| Intermediate / Resistant | 5 (15.2) | 15 (30.0) | ||
| Levofloxacin (n=74) | 0.651 | 1.29 | ||
| Susceptible | 22 (78.5) | 34 (73.9) | ||
| Intermediate / Resistant | 6 (21.5) | 12 (26.1) | ||
| Ceftazidime (n=77) | 0.336 | 1.68 | ||
| Susceptible | 9 (29.0) | 9 (19.6) | ||
| Intermediate / Resistant | 22 (71.0) | 37 (80.4) | ||
TMP-SXT: Trimethoprim-sulfamethoxazole, OR: Odds ratio.